Asset profile

Trastuzumab rezetecan

Antibody–drug conjugate

Phase 3underway

Evidence outlook · registrational

HR+/HER2- Metastatic Breast Cancer: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2028-12-31.

Also in development:Non-Small Cell Lung Cancer · Phase 3

How the evidence outlook works ↗

Featured trials

Research

Unlock featured-trial analysis

Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.

Upcoming events

(50 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (7)

August 2026 (1)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2026-08-31 · NCT06718933 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2026 (1)

Phase 2Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Breast CancerRecruiting

Est. primary completion 2026-09 · NCT06649331 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2026 (2)

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2026-10 · NCT07129187 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2026-10-31 · NCT06222879 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (3)

Phase 1/2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2026-12 · NCT05482568 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Triple-negative Breast CancerRecruiting

Est. primary completion 2026-12-31 · NCT05076682 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and TaxaneActive not recruiting

Est. primary completion 2026-12-31 · NCT05424835 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (15)

March 2027 (3)

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2027-03 · NCT07416253 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-03 · NCT06433609 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2027-03 · NCT07305246 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2027 (1)

Phase 2HER2-positive Breast CancerNot yet recruiting

Est. primary completion 2027-05-31 · NCT06973525 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2027 (2)

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2027-06-01 · NCT06975475 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2027-06-01 · NCT06975462 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2027 (2)

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2027-07 · NCT07528898 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-07-01 · NCT07630077 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2027 (1)

Phase 3HER2-PositiveRecurrent or Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-10 · NCT06057610 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (6)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-12 · NCT07281209 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Early-stage or Locally Advanced HER2-positive Breast CancerActive not recruiting

Est. primary completion 2027-12 · NCT07196774 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-12-31 · NCT07489703 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2027-12-31 · NCT07307287 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Triple-negative Breast CancerRecruiting

Est. primary completion 2027-12-31 · NCT05749588 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (18)

January 2028 (1)

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2028-01-15 · NCT07466927 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2028 (2)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-02-01 · NCT07383818 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast CancerNot yet recruiting

Est. primary completion 2028-02-01 · NCT07466303 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2028 (2)

Phase 3PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast CancerRecruiting

Est. primary completion 2028-03 · NCT07111832 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2028-03-31 · NCT06788197 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2028 (3)

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2028-06 · NCT07618923 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-06 · NCT07497386 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-06-30 · NCT07037199 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2028 (1)

Phase 2Metastatic Breast Cancer With HER2 PositiveNot yet recruiting

Est. primary completion 2028-08-30 · NCT07132242 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2028 (3)

Phase 1/2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2028-09-30 · NCT07177950 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Breast Cancer, Triple Negative Breast Cancer (TNBC)Not yet recruiting

Est. primary completion 2028-09-30 · NCT07669610 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Breast Cancer, Triple Negative Breast Cancer (TNBC)Not yet recruiting

Est. primary completion 2028-09-30 · NCT07760844 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2028 (1)

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2028-10-15 · NCT07317778 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2028 (5)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-12-30 · NCT05769010 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2028-12-31 · NCT07631884 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HER2-positive Early Breast CancerRecruiting

Est. primary completion 2028-12-31 · NCT07340398 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2028-12-31 · NCT07560475 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2028-12-31 · NCT07382687 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (3)

January 2029 (1)

Phase 2Breast Cancer, HER2-positive Breast CancerNot yet recruiting

Est. primary completion 2029-01-31 · NCT07417241 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2029 (1)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2029-05-01 · NCT06927180 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2029 (1)

Phase 2HER2-positive Breast CancerRecruiting

Est. primary completion 2029-06 · NCT07647263 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (5)

April 2030 (1)

Phase 3HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant TherapyActive not recruiting

Est. primary completion 2030-04 · NCT06126640 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2030 (1)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2030-06-15 · NCT07203729 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2030 (1)

Phase 2HER2-positive Advanced Breast Cancer, Brain Metastases, RadiotherapyRecruiting

Est. primary completion 2030-07-30 · NCT07100600 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2030 (2)

Phase 3Triple Negative Breast CancerNot yet recruiting

Est. primary completion 2030-12 · NCT07679360 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HER2-positive Breast CancerNot yet recruiting

Est. primary completion 2030-12-30 · NCT07179939 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2031 (2)

June 2031 (1)

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2031-06 · NCT07630103 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2031 (1)

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2031-12-31 · NCT07766772 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.